What's 'meaningful' pharma innovation? House subcommittee talks incentives
The health subcommittee of the House Ways and Means Committee heard testimony on Wednesday from five witnesses, including advocates and doctors, while examining federal policies on drug innovation, pricing and access.
As PBM reforms continue in both the House and Senate, the Republican-controlled House subcommittee kicked off the hearing with chair Vern Buchanan (R-FL) saying that the government should do everything it can to promote innovation and patient access. The congressman slammed lack of access as a result of federal policies, particularly on Alzheimer’s therapies and CMS’ Jan. 2022 decision to only cover amyloid-targeting monoclonal antibodies in the context of a clinical trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.